Predictors of Weight Loss and Metabolic Health After Bariatric Surgery

Korábbi kezelés

• Pregnancy anticipated in the first two years following surgery
  • A potential subject who meet the following criteria will be excluded from participation in the subgroup of this study:
• Use of any medication except for statins, antihypertensives (except for Angiotensine converting enzyme (ACE)- or angiotensin receptor blockers) and thyroid hormone

Más betegség

• Any actual medical condition except for obesity related health issues or well treated hypothyroidism
• Coagulation disorders and/or use anticoagulants
• Diabetes mellitus type 2

• Ability to provide informed consent
• Patient is ≥ 18 and ≤ 75 years old
• BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
• Scheduled for primary bariatric procedure: Roux-en-Y gastric bypass (RYGB) or Sleeve Gastrectomy (SG)
• Stable weight 3 months prior to inclusion weight (<10% change in body weight for 3 months prior to assessments)
  • In order to be eligible to participate in the subgroup of this study, we will use the following inclusion criteria:
• Ability to provide informed consent
• Patient is ≥ 18 and ≤ 75 years old
• BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity
• Patients scheduled for RYGB
• Patients who are insulin resistant (impaired fasting glucose (> 5.6 mmol/L) or fasting insulin > 74 pmol/L)
• Postmenopausal women (to prevent bias due to the effect of sex hormones on insulin sensitivity)